FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: a multicenter randomized clinical trial (MONITOR-RCT)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508591-11-00

Acronym

2023-508591-11-00

Enrollment

420

Registered

2024-10-14

Start date

2025-02-25

Completion date

Unknown

Last updated

2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic breast cancer

Brief summary

Overall survival

Detailed description

Quality of life, Time and exposure to oncologic treatment, Cost-effectiveness

Interventions

DRUGFLUDEOXYGLUCOSE (18F)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Quality of life, Time and exposure to oncologic treatment, Cost-effectiveness	—

Countries

Denmark, Germany, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026